​

Palvella Therapeutics Stock (NASDAQ:PVLA)

ForecastOwnershipFinancialsChart
Palvella Therapeutics by TradingView

Previous Close

$127.05

52W Range

$20.20 - $151.18

50D Avg

$120.22

200D Avg

$83.39

Market Cap

$1.46B

Avg Vol (3M)

$319.70K

Beta

-0.20

Div Yield

-

PVLA Company Profile

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

14

IPO Date

Jan 02, 2015

Website

PVLA Performance

PVLA Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income-$-14.10M$-11.87M
Net Income$-41.72M$-17.43M$18.69M
EBITDA-$-13.12M$18.69M
Basic EPS$-3.71$-7.83$14.74
Diluted EPS$-3.71$-7.83$14.74

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
EYPTEyePoint Pharmaceuticals, Inc.
NBTXNanobiotix S.A.
KURAKura Oncology, Inc.
SPRYARS Pharmaceuticals, Inc.
ABUSArbutus Biopharma Corporation
RZLTRezolute, Inc.
GHRSGH Research PLC
TYRATyra Biosciences, Inc.
PROKProKidney Corp.
SVRASavara Inc.